Identification of Small Nucleolar RNA SNORD60 as a Potential Biomarker and Its Clinical Significance in Lung Adenocarcinoma

Abstract

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths in the world and often diagnosed at an advanced stage, so it is urgent to explore the pathogenesis and new diagnostic biomarkers. Accumulated evidences suggested that small nucleolar RNAs (snoRNAs) played a key role in the development and progression of NSCLC. To examine differential expression snoRNA profile and identify snoRNAs with clinical significance in lung adenocarcinoma (LUAD), The Cancer Genome Atlas (TCGA) LUAD RNA sequencing dataset was used to investigate differential expression snoRNA signatures and compared with snoRNA PCR array analysis in pair-matched LUAD tissues. The diagnostic ability of SONRD60 was assessed using a receiver operating characteristic (ROC) curve. The Kaplan-Meier method was used to plot survival curves. Univariate and multivariate Cox regression analyses were used to investigate the prognostic effect of SNORD60 expression on LUAD. The results showed that SNORD60 was a significantly upregulated snoRNA after intersection analysis in LUAD cases. SNORD60 has 74.2% sensitivity and 75.3% specificity for the diagnosis of LUAD. Increased SNORD60 expression was linked with lymph node metastases and the TNM stage ( P < 0.05 ). Pathological T category and lymph node metastases were independent prognostic factors for overall survival in a multivariate Cox regression study. Our findings demonstrated that SNORD60, a small nucleolar RNA, has an oncogenic function in LUAD and might be used as a new early diagnostic biomarker for LUAD.

Comprehensive analysis to identify GNG7 as a prognostic biomarker in lung adenocarcinoma correlating with immune infiltrates

“…Here, our study based on GNG7 is similar to, but more distinctive from, the newly identified biomarkers for LUAD in the latest literatures. In our study, we demonstrated GNG7 as an independent prognostic risk factor in LUAD (Supplementary Table S4) (Wan et al, 2021;Tian W. et al, 2022;Zhang et al, 2022;Zhou et al, 2022). Moreover, we constructed a nomogram combined with other clinical independent prognostic risk factors to predict the prognosis of LUAD patients reliably.…”

Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in Cancer: A Systematic Review and Meta-Analysis

“…We also excluded 79 basic studies and 26 reviews from the remaining 105 eligible studies. Finally, we included a total of 49 studies in our qualitative synthesis, with 21 studies focused on diagnosis, 9 – 29 and 41 studies focused on prognosis. 11 , 13 – 15 , 17 , 18 , 20 , 22 , 24 , 25 , 27 , 28 , 30 – 56 Figure 1 provided detailing information about the selection process, which based on preferred reporting items for systematic reviews and meta-analyses (PRISMA) standards.…”

Knowledge mapping and current trends of global research on snoRNA in the field of cancer

“…Increased expression of SNORA42 and SNORA71A in lung cancer was found to be associated with poor prognosis 40 , 47 . Another study on lung cancer implicated SNORD60 in the causation of lung adenocarcinoma and highlighted its role as a marker of poor prognosis 48 . A study identified the prognostic value of HBII-239 snoRNA in T cell lymphoma, and its elevated level indicated a good prognosis 49 .…”